PillCam SBC System Functionality in Established and Suspected IBD Patients
NCT ID: NCT02742714
Last Updated: 2017-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
54 participants
INTERVENTIONAL
2016-07-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Fifty established and suspected IBD patients (at least half of them with established crohn disease (CD)) with active or quiescent disease activity, aged 18 years and up, with no symptomatic stricture or known obstruction that would prevent capsule passage will be enrolled in up to 6 medical sites in Israel and Europe.
Patients will undergo bowel prep, followed by a PillCam SBC capsule examination. Patency capsule may precede PillCam SBC ingestion according to physician discretion.
The PillCam Software videos will be evaluated by local site reader following a Subjective Assessment Form fulfillment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PillCam SBC
The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
PillCam SBC system
The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PillCam SBC system
The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has known crohn disease and/ or ulcerative colitis Or
* Patient suspected to have inflammatory bowel disease and suffers from either:
* Diarrhea for more than 6 weeks and/or
* Abdominal pain for more than 6 weeks and/or
* Extra-luminal manifestations of IBD including: erythema nodosum, pyoderma gangrenosum, arthritis, peri-anal disease, uveitis, aphthous stomatitis and
* Suffers from at least one of the symptoms / lab abnormalities listed below:
* Positive inflammatory marker (ESR, C reactive protein (CRP), thrombocytosis, fecal lactoferrin, fecal calprotectin) within 3 months prior to enrollment
* Unexplained anemia (less than normal limits) within 3 months prior to enrollment
* Hypoalbuminemia (\<3.5 g/dl) within 3 months of enrollment
* Positive IBD serology within 3 months of enrollment
* Recurrent Fevers
* Unexplained weight loss
* Gastro-intestinal bleeding including melena and/or hematochezia and/or fecal occult blood test (FOBT) positive.
* Chronic perianal disease (fistula, fissure, peri-rectal abscess)
* Abnormal imaging of Gastrointestinal (GI) tract (e.g. Magnetic resonance enterography (MRE)) suggestive of inflammatory bowel disease
* For known CD patients, proven patency by the patency capsule or another approach deemed clinically acceptable by the investigator, e.g. CT enterography, MRE performed within the 90 days prior to enrollment
* Patients agree to sign consent form
Exclusion Criteria
* Stool positive for Ova \&Parasite and for Clostridium difficile toxin within 3 months of enrollment
* Other known infectious cause of symptoms
* Known or suspected intestinal obstruction
* Non-steroidal anti-inflammatory drugs (twice weekly or more) during the 4 weeks preceding enrollment.
* Suspected or known GI stricture, followed by patency capsule study or other imaging study that could not prove patency of the GI tract
* Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule
* Patient with known gastrointestinal motility disorders
* Subjects with known or suspected delayed gastric emptying
* Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions
* Patient has any allergy or other known contraindication or intolerance to the medications used in the study
* Patient has any condition, which precludes compliance with study and/or device instructions
* Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception
* Concurrent participation in another clinical trial using any investigational drug or device
* Patient suffers from a life threatening condition
* Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic - MITG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abraham Eliakim, Prof.
Role: PRINCIPAL_INVESTIGATOR
Sheba Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shaare Zedek Medical Center
Jerusalem, , Israel
Sheba Medical Center
Ramat Gan, , Israel
The Tel-Aviv Sourasky Medical Center
Tel Aviv, , Israel
Fondazione Policlinico Universitario Agostino Gemelli
Rome, , Italy
Hospital de Navarra
Pamplona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVGIRD0546
Identifier Type: -
Identifier Source: org_study_id